What Makes Sarepta Therapeutics’ Presentation Design Effective in Communicating EMBARK Study Results?

An effective therapeutics presentation design communicates clinical study results by combining visual hierarchy, precise data storytelling, and audience-calibrated language into a unified framework. When a gene therapy or rare-disease sponsor presents pivotal trial outcomes — such as those from a confirmatory study in a pediatric neuromuscular population — the design must guide reviewers through statistical endpoints, safety profiles, and functional outcome measures without overwhelming them. The most successful designs anchor every slide to a single claim, supported by clearly labeled charts, and use color coding to distinguish treated cohorts from placebo or natural history controls, making the core finding immediately legible.

The foundational challenge in clinical-trial presentation design is translating dense biostatistical output into a narrative that is simultaneously rigorous and accessible. Regulatory audiences, scientific advisory boards, and patient advocacy groups each need different entry points into the same data. Effective design accounts for this by layering information: headline numbers appear in large, bold typography at the top of each figure, while confidence intervals, p-values, and sample sizes are placed in a secondary tier that technically trained readers can inspect without distracting lay stakeholders. A common mistake is treating every data point as equally important, which produces slides that look like appendix tables rather than persuasive evidence summaries.

Data visualization choices carry enormous weight in a pivotal-study readout. Kaplan-Meier survival curves, waterfall plots showing individual patient responses, and bar charts comparing mean change from baseline each serve different rhetorical purposes. A waterfall plot, for instance, is particularly powerful when the sponsor wants to show that treatment benefit is consistent across most patients in the cohort rather than driven by outliers — a concern that arises frequently in small rare-disease trials where n may be under 30. Functional outcome measures such as timed motor assessments (like a 10-meter walk test scored in seconds) should be plotted on axes that start at a clinically meaningful reference point, not at zero, to prevent visual distortion of the effect size. A 1.5-second improvement in gait speed, for example, can appear trivial on a 0-to-30-second axis but clinically substantial when the axis spans 8 to 14 seconds.

• Use a single-claim slide structure where the slide title states the conclusion (e.g., ‘Treated patients maintained ambulation 18 months longer than natural history controls’) rather than a neutral descriptor like ‘Efficacy Results.’
• Apply a consistent two-color palette — one color for the treatment arm and one for the control — across every figure in the deck so reviewers build visual memory without re-reading legends.
• Place confidence intervals and p-values in a footnote-weight font beneath each figure, ensuring statistical detail is present for auditors but does not compete with the primary visual message.
• Use annotated callout boxes on Kaplan-Meier curves to mark clinically meaningful events (e.g., loss of ambulation, first hospitalization) at the exact time-point they occur, grounding statistical curves in real patient milestones.
• Include a ‘patient journey’ slide early in the deck that translates the primary endpoint into plain language — for example, converting a functional motor score into ‘the ability to climb stairs independently’ — before introducing numerical results.
• Standardize axis scaling across all efficacy figures so that comparisons between secondary endpoints do not mislead through inconsistent visual magnification.
• Dedicate a distinct section to the safety profile with a consistent adverse-event taxonomy, using a structured table rather than prose so reviewers can scan severity grades, incidence rates, and discontinuations in parallel columns.

The practical takeaway is that effective clinical-study presentation design is not decoration — it is an argument architecture that determines whether reviewers reach the correct conclusion efficiently. Your immediate next step should be to audit your existing slide deck against the single-claim-per-slide rule: if any slide title is a noun phrase rather than a declarative statement, rewrite it first. Note that this approach is less applicable in early-phase exploratory presentations, where data are preliminary and multiple hypotheses need to remain open — in those contexts, a more exploratory, multi-hypothesis layout is appropriate and epistemic humility should be visually signaled throughout.